CAPN9: A Potential Drug Target and Biomarker (G10753)

Target Name: CAPN9

NCBI ID: G10753

CAPN9

CAPN9: A Potential Drug Target and Biomarker

Calpain large subunit-4 (CAPN9) is a protein that is expressed in various tissues and cell types in the human body. It is a member of the superfamily of calpins, which are a family of transmembrane proteins that play a significant role in intracellular signaling and signaling pathways. CAPN9 is characterized by its large size and its unique subunit structure, which consists of four distinct subunits that are held together by disulfide bonds.

The CAPN9 protein is involved in a wide range of physiological processes in the body, including cell signaling, cytoskeletal organization, and intracellular signaling pathways. It is a key regulator of the cytoskeleton, which is responsible for the structure and function of cells, and it is involved in the regulation of cell signaling pathways that are critical for cellular growth, differentiation, and survival.

CAPN9 is also involved in the regulation of cytoskeletal organization, which is the process by which cells organize their cytoskeletons into a highly specialized structure that is essential for cell movement, mechanical stability, and other physiological processes. The cytoskeleton is composed of a network of filaments and cables that are held together by disulfide bonds, and it is managed by a variety of proteins that are involved in its regulation.

CAPN9 is a potential drug target because of its involvement in cell signaling pathways and cytoskeletal organization. Many diseases are caused by the disruption of these signaling pathways, and CAPN9 may be a useful target for the development of new treatments. For example, CAPN9 has been shown to be involved in the regulation of cell signaling pathways that are critical for cancer growth and progression.

In addition to its potential as a drug target, CAPN9 may also be a biomarker for certain diseases. The cytoskeleton is a highly specialized structure that is expressed in many different cell types, and it is often used as a biomarker for the presence of certain diseases. For example, the cytoskeleton is often used as a biomarker for the diagnosis of certain types of cancer, such as breast cancer and lung cancer.

CAPN9 may also be used as a biomarker for other diseases, such as neurodegenerative diseases and autoimmune diseases. The cytoskeleton is involved in the regulation of many different signaling pathways, and it is possible that CAPN9 may be involved in the regulation of these pathways in these diseases.

In conclusion, CAPN9 is a protein that is expressed in various tissues and cell types in the human body. It is a member of the superfamily of calpins and is involved in a wide range of physiological processes in the body, including cell signaling, cytoskeletal organization, and intracellular signaling pathways. As a result, CAPN9 may be a useful target for the development of new treatments for a variety of diseases. In addition, CAPN9 may also be a useful biomarker for the diagnosis of certain diseases. Further research is needed to fully understand the role of CAPN9 in these processes and to develop new treatments.

Protein Name: Calpain 9

Functions: Calcium-regulated non-lysosomal thiol-protease

The "CAPN9 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CAPN9 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets